Figure 6. Inhibition of Akt/mTOR signaling pathway and disruption of Beclin-1/Mcl-1 complex via inhibition of STAT3 signaling pathway by CCB in MDR cells.

CEM/VLB₁₀₀ (A) or MCF7-MDR cells (B) were treated with increasing doses of CCB for 36 h, and Atg7, Akt/p-Akt, mTOR/p-mTOR, p70S6K/p-p70S6K, and 4E-BP1/p-4E-BP1 levels were determined by western blotting. The expressions of STAT3/p-STAT3 and Mcl-1 in two MDR cells treated with increasing doses of CCB for 36 h (C and D) were determined by western blot analysis (E). Mcl-1 or Beclin-1 were immunoprecipitated from CEM/VLB₁₀₀ cells treated with CCB (25 μM for 36 h) and analyzed for the presence of Mcl-1 or Beclin-1, respectively.